Physician profile
Prasontha Bathini
NPI 1710977673
$1,756.23
in general payments reported to CMS, 2019-2025
18 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $67.48 · 2021: $188 · 2022: $267 · 2023: $444 · 2024: $324 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $290.26 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $263.43 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $199.15 | 2021-2024 | Verquvo |
| Heartflow, INC. | $153.68 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $147.73 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $121.28 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.37 | 2019-2024 | Lifevest |
| Amgen INC. | $92.01 | 2022-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $74.20 | 2020-2024 | Andexxa |
| Impulse Dynamics (USA) INC. | $72.09 | 2023 | Optimizer |
| Pfizer INC. | $47.32 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $36.11 | 2021-2022 | |
| Scpharmaceuticals INC. | $32.45 | 2024 | |
| Zoll Circulation INC | $30.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.76 | 2024 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $26.34 | 2023 | Injectafer |
| Boston Scientific Corporation | $21.72 | 2023 | |
| Biotronik INC. | $14.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasontha Bathini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.